What is the difference between vitamin K1 (phylloquinone) and vitamin K2 (menaquinone) in terms of clinical use and supplementation?

Differences Between Vitamin K1 and K2: Clinical Use and Supplementation

Vitamin K1 (phylloquinone) and vitamin K2 (menaquinone) differ primarily in their sources, bioavailability, and tissue-specific actions, with K2 showing greater effectiveness for extrahepatic functions while K1 is the preferred form for managing anticoagulation and bleeding risks.

Sources and Chemical Structure

Vitamin K1 (Phylloquinone)

• Found primarily in plant foods, especially green leafy vegetables and vegetable oils 1, 2
• Single form with consistent structure
• Primary dietary source of vitamin K for most people 3

Vitamin K2 (Menaquinone)

• Family of compounds (MK-4 through MK-13) with varying side chain lengths 3
• Produced by anaerobic bacteria in the gut and found in fermented foods and animal products 3, 4
• Accounts for up to 25% of total vitamin K intake 5

Pharmacokinetics and Bioavailability

Vitamin K1

• Shorter half-life in circulation
• Lower bioavailability compared to K2
• Primarily directed to the liver for clotting factor synthesis 5

Vitamin K2

• Longer half-life in circulation
• Better bioavailability than K1
• More effective distribution to extrahepatic tissues 5

Clinical Functions and Applications

Vitamin K1 (Phylloquinone)

• Primary clinical use: Management of anticoagulation and bleeding risk
• Gold standard for reversing warfarin anticoagulation 6
• Recommended form for treating vitamin K deficiency bleeding
• Dosing for warfarin reversal:
  • For INR 4-10 without bleeding: 1-2.5 mg orally 6
  • For INR >10 without significant bleeding: 3-5 mg orally 6
  • For serious bleeding: 10 mg by slow IV infusion 6

Vitamin K2 (Menaquinone)

• Primary clinical use: Bone and cardiovascular health
• More effective in activating extrahepatic vitamin K-dependent proteins 5
• Particularly important for:
  • Calcium metabolism
  • Bone mineralization
  • Vascular health 3, 5

Supplementation Recommendations

General Population

• Current dietary reference values are based primarily on K1 requirements 5
• Adequate intake (AI) according to EFSA: 1 μg/kg body weight per day 2
• IOM recommendations: 120 μg for adult males, 90 μg for adult females 2

Special Populations

• Cystic fibrosis patients:

  • Infants: 0.3-1 mg/day of vitamin K1
  • Children and adults: 1-10 mg/day of vitamin K1 1
  • Higher doses for those with liver disease or on long-term antibiotics

• Patients on warfarin:

  • Should maintain consistent vitamin K intake
  • Avoid sudden changes in vitamin K consumption
  • May require monitoring when starting supplementation 2

• Infants:

  • All exclusively breastfed infants should receive vitamin K supplementation
  • Breast milk contains low levels of vitamin K (primarily K1) 7
  • Infant formulas contain higher levels of K1 than breast milk 7

Clinical Monitoring

• No single agreed standard for vitamin K status assessment 2
• Options include:
  • Serum vitamin K levels (concentrations <0.15 μg/L indicate deficiency) 2
  • PIVKA-II (Protein Induced by Vitamin K Absence)
  • Undercarboxylated osteocalcin
  • Prothrombin time (insensitive, only abnormal in severe deficiency) 1

Safety Considerations

• Vitamin K1 and K2 are not associated with toxicity at supplemental doses 2
• Rare anaphylactoid reactions have been reported with IV vitamin K1 administration 2
• Vitamin K3 (synthetic form) is toxic and no longer available for clinical use 2

Key Clinical Takeaways

• For anticoagulation reversal and bleeding risk management, vitamin K1 is the preferred form
• For bone and cardiovascular health, vitamin K2 may offer advantages over K1
• Current recommendations don't distinguish between K1 and K2 requirements despite their different metabolic roles
• Both forms contribute to overall vitamin K status but have different tissue specificities
• Future dietary recommendations may need to consider both K1 and K2 separately 5